Dr Hope Rugo speaks to ecancer about a phase 3 trial that evaluated adagloxad simolenin, a globo H-targeting cancer vaccine, in combination with the adjuvant OBI-821 in patients with high-risk, early-stage triple-negative breast cancer.

While the treatment was generally well tolerated and demonstrated a safety profile comparable to standard of care, it did not improve clinical outcomes.

Invasive disease-free survival and overall survival were similar between treatment and control groups, and the study was ultimately stopped early after meeting predefined futility criteria.

These findings highlight the challenges of translating cancer vaccines into meaningful clinical benefit in this setting, while reinforcing the importance of continued research to improve outcomes for patients with high-risk triple-negative breast cancer.